## Laurent Remontet

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8805301/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Modeling excess hazard with timeâ€ŧoâ€cure as a parameter. Biometrics, 2021, 77, 1289-1302.	1.4	Ο
2	Oral nomegestrol acetate and transdermal 17-beta-estradiol for preventing post-partum relapses in multiple sclerosis: The POPARTMUS study. Multiple Sclerosis Journal, 2021, 27, 1458-1463.	3.0	8
3	How to produce sound predictions of incidence at a district level using either health care or mortality data in the absence of a national registry: the example of cancer in France. International Journal of Epidemiology, 2021, 50, 279-292.	1.9	1
4	Relationship between adverse drug reactions and unlicensed/off-label drug use in hospitalized children (EREMI): A study protocol. Therapie, 2021, 76, 675-685.	1.0	7
5	Effects of Age and Disease Duration on Excess Mortality in Patients With Multiple Sclerosis From a French Nationwide Cohort. Neurology, 2021, 97, e403-e413.	1.1	10
6	Socioeconomic Environment and Survival in Patients with Digestive Cancers: A French Population-Based Study. Cancers, 2021, 13, 5156.	3.7	8
7	Multidimensional penalized splines for incidence and mortality-trend analyses and validation of national cancer-incidence estimates. International Journal of Epidemiology, 2020, 49, 1294-1306.	1.9	11
8	Preoperative Topical Estrogen Treatment vs Placebo in 244 Children With Midshaft and Posterior Hypospadias. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 2422-2429.	3.6	5
9	Flexible and structured survival model for a simultaneous estimation of non-linear and non-proportional effects and complex interactions between continuous variables: Performance of this multidimensional penalized spline approach in net survival trend analysis. Statistical Methods in Medical Research, 2019, 28, 2368-2384.	1.5	24
10	For a sound use of health care data in epidemiology: evaluation of a calibration model for count data with application to prediction of cancer incidence in areas without cancer registry. Biostatistics, 2019, 20, 452-467.	1.5	6
11	On a general structure for hazard-based regression models: An application to population-based cancer research. Statistical Methods in Medical Research, 2019, 28, 2404-2417.	1.5	24
12	Multi-Dimensional Penalized Hazard Model with Continuous Covariates: Applications for Studying Trends and Social Inequalities in Cancer Survival. Journal of the Royal Statistical Society Series C: Applied Statistics, 2019, 68, 1233-1257.	1.0	23
13	Time-to-cure and cure proportion in solid cancers in France. A population based study. Cancer Epidemiology, 2019, 60, 93-101.	1.9	16
14	Trends in probabilities of death owing to cancer and owing to other causes in patients with colon cancer. European Journal of Gastroenterology and Hepatology, 2019, 31, 570-576.	1.6	0
15	Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study. Lancet Oncology, The, 2019, 20, 100-109.	10.7	701
16	Socioeconomic environment and disparities in cancer survival for 19 solid tumor sites: An analysis of the French Network of Cancer Registries (FRANCIM) data. International Journal of Cancer, 2019, 144, 1262-1274.	5.1	35
17	survPen: an R package for hazard and excess hazard modelling with multidimensional penalized splines. Journal of Open Source Software, 2019, 4, 1434.	4.6	19
18	A new approach to estimate time-to-cure from cancer registries data. Cancer Epidemiology, 2018, 53, 72-80	1.9	25

LAURENT REMONTET

#	Article	IF	CITATIONS
19	Describing the association between socioeconomic inequalities and cancer survival: methodological guidelines and illustration with population-based data. Clinical Epidemiology, 2018, Volume 10, 561-573.	3.0	21
20	New insights into survival trend analyses in cancer population-based studies: the SUDCAN methodology. European Journal of Cancer Prevention, 2017, 26, S9-S15.	1.3	7
21	Survival of solid cancer patients in France, 1989–2013: a population-based study. European Journal of Cancer Prevention, 2017, 26, 461-468.	1.3	47
22	Focus on an unusual rise in pancreatic cancer incidence in France. International Journal of Epidemiology, 2017, 46, 1764-1772.	1.9	49
23	Sensitivity and specificity of different methods for cystic fibrosis-related diabetes screening: is the oral glucose tolerance test still the standard?. Journal of Pediatric Endocrinology and Metabolism, 2017, 30, 27-35.	0.9	30
24	Performance of two formal tests based on martingales residuals to check the proportional hazard assumption and the functional form of the prognostic factors in flexible parametric excess hazard models. Biostatistics, 2017, 18, 505-520.	1.5	5
25	A multilevel excess hazard model to estimate net survival on hierarchical data allowing for non-linear and non-proportional effects of covariates. Statistics in Medicine, 2016, 35, 3066-3084.	1.6	37
26	Cancer incidence in France over the 1980–2012 period: Hematological malignancies. Revue D'Epidemiologie Et De Sante Publique, 2016, 64, 103-112.	0.5	33
27	Low phosphatemia in extremely low birth weight neonates: A risk factor for hyperglycemia?. Clinical Nutrition, 2016, 35, 1059-1065.	5.0	13
28	Changes in dynamics of excess mortality rates and net survival after diagnosis of follicular lymphoma or diffuse large B-cell lymphoma: comparison between European population-based data (EUROCARE-5). Lancet Haematology,the, 2015, 2, e481-e491.	4.6	33
29	Framework and optimisation procedure for flexible parametric survival models. Statistics in Medicine, 2015, 34, 3376-3377.	1.6	3
30	Incidence of major smoking-related cancers: Trends among adults aged 20–44 in France from 1982 to 2012. Cancer Epidemiology, 2015, 39, 707-713.	1.9	13
31	Trends in excess mortality in follicular lymphoma at a population level. European Journal of Haematology, 2015, 94, 120-129.	2.2	11
32	A joint frailty model to estimate the recurrence process and the diseaseâ€specific mortality process without needing the cause of death. Statistics in Medicine, 2014, 33, 3147-3166.	1.6	13
33	Cancer incidence and mortality in France over the 1980–2012 period: Solid tumors. Revue D'Epidemiologie Et De Sante Publique, 2014, 62, 95-108.	0.5	184
34	Early parenteral lipids and growth velocity in extremely-low-birth-weight infants. Clinical Nutrition, 2014, 33, 502-508.	5.0	28
35	National cancer incidence is estimated using the incidence/mortality ratio in countries with local incidence data: Is this estimation correct?. Cancer Epidemiology, 2013, 37, 270-277.	1.9	17
36	Cancer net survival on registry data: Use of the new unbiased Poharâ€Perme estimator and magnitude of the bias with the classical methods. International Journal of Cancer, 2013, 132, 2359-2369.	5.1	62

LAURENT REMONTET

#	Article	IF	CITATIONS
37	Description of an approach based on maximum likelihood to adjust an excess hazard model with a random effect. Cancer Epidemiology, 2013, 37, 449-456.	1.9	4
38	Probabilities of dying from cancer and other causes in French cancer patients based on an unbiased estimator of net survival: A study of five common cancers. Cancer Epidemiology, 2013, 37, 857-863.	1.9	30
39	Cancer incidence estimation at a district level without a national registry: A validation study for 24 cancer sites using French health insurance and registry data. Cancer Epidemiology, 2013, 37, 99-114.	1.9	16
40	Author's reply to: Estimating net survival in population-based cancer studies. International Journal of Cancer, 2013, 133, 522-523.	5.1	0
41	Unbiased estimates of longâ€ŧerm net survival of solid cancers in France. International Journal of Cancer, 2013, 132, 2370-2377.	5.1	31
42	Farnesoid X Receptor Targeting for Hepatitis C: Study Protocol for a Proof-of-concept Trial. Therapie, 2012, 67, 423-427.	1.0	3
43	Joint use of epidemiological and hospital medico-administrative data to estimate prevalence. Application to French data on breast cancer. Cancer Epidemiology, 2012, 36, 116-121.	1.9	10
44	Estimating net survival: the importance of allowing for informative censoring. Statistics in Medicine, 2012, 31, 775-786.	1.6	74
45	Trends in the incidence of digestive cancers in France between 1980 and 2005 and projections for the year 2010. European Journal of Cancer Prevention, 2011, 20, 375-380.	1.3	28
46	Changes in the dynamics of the excess mortality rate in chronic phase-chronic myeloid leukemia over 1990-2007: a population study. Blood, 2011, 118, 4331-4337.	1.4	33
47	Competing risk models to estimate the excess mortality and the first recurrent-event hazards. BMC Medical Research Methodology, 2011, 11, 78.	3.1	12
48	Reliability of recording uterine cancer in death certification in France and age-specific proportions of deaths from cervix and corpus uteri. Cancer Epidemiology, 2011, 35, 243-249.	1.9	5
49	A Suitable Approach to Estimate Cancer Incidence in Area without Cancer Registry. Journal of Cancer Epidemiology, 2011, 2011, 1-11.	1.1	20
50	A dietary supplement to improve the quality of sleep: a randomized placebo controlled trial. BMC Complementary and Alternative Medicine, 2010, 10, 29.	3.7	29
51	Changes in the risk of death from cancer up to five years after diagnosis in elderly patients: A study of five common cancers. International Journal of Cancer, 2010, 127, 924-931.	5.1	28
52	Flexible modeling of competing risks in survival analysis. Statistics in Medicine, 2010, 29, 2453-2468.	1.6	28
53	Thyroid cancer: is the incidence rise abating?. European Journal of Endocrinology, 2009, 160, 71-79.	3.7	47
54	Incidence and survival of gastric non-Hodgkin's lymphoma: A population-based study from the Association of the French Cancer Registries (FRANCIM). Acta Oncológica, 2009, 48, 977-983.	1.8	5

LAURENT REMONTET

#	Article	IF	CITATIONS
55	Conditional relative survival of cancer patients and conditional probability of death. Cancer, 2009, 115, 4616-4624.	4.1	37
56	Breast cancer incidence using administrative data: correction with sensitivity and specificity. Journal of Clinical Epidemiology, 2009, 62, 660-666.	5.0	67
57	Is Pneumonectomy After Induction Chemotherapy for Non-small Cell Lung Cancer a Reasonable Procedure? A Multicenter Retrospective Study of 228 Cases. Journal of Thoracic Oncology, 2009, 4, 1496-1503.	1.1	15
58	Hazard regression model and cure rate model in colon cancer relative survival trends: are they telling the same story?. European Journal of Epidemiology, 2008, 23, 251-259.	5.7	11
59	Artefact-free trends in breast cancer incidence over two decades in a whole French Département. Breast, 2008, 17, 580-586.	2.2	2
60	Cancer incidence and mortality in France over the period 1980–2005. Revue D'Epidemiologie Et De Sante Publique, 2008, 56, 159-175.	0.5	418
61	Prognostic factors and long-term results of pulmonary metastasectomy for pediatric histologiesâ~†. European Journal of Cardio-thoracic Surgery, 2008, 34, 1240-1246.	1.4	39
62	Trends in incidence of digestive cancers in France. European Journal of Cancer Prevention, 2008, 17, 13-17.	1.3	26
63	Effect of Age, Gender, and Diabetes on Excess Death in End-Stage Renal Failure. Journal of the American Society of Nephrology: JASN, 2007, 18, 2125-2134.	6.1	146
64	Estimating infra-national and national thyroid cancer incidence in France from cancer registries data and national hospital discharge database. European Journal of Epidemiology, 2007, 22, 607-614.	5.7	27
65	Incidence of gastrointestinal cancers in France. Gastroenterologie Clinique Et Biologique, 2004, 28, 877-881	0.9	102